摘要
异基因造血干细胞移植(allogeneic hematopoietic stem cell transplantation, allo-HSCT)通过移植物抗白血病效应(graft-versus-leukemia, GVL)实现了对血液系统恶性肿瘤的治愈效果,执行GVL的供者T淋巴细胞经历活化扩增及效应的过程后清除白血病细胞,成为中高危血液病有效的治疗手段。T淋巴细胞是发挥移植物抗白血病的主要效应细胞,且在移植后感染、GVHD和复发中发挥重要作用。PD-1、TIM-3、LAG-3、CD47通过不同机制抑制T细胞发挥免疫效应,所以异基因造血干细胞移植后T淋巴细胞及上述免疫检查点的重建规律的研究对于预后有重大意义。
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has achieved curative effects on he-matologic malignancies through graft-versus-leukemia (GVL), and the donor T lymphocytes of GVL undergo the process of activation, expansion and effector to remove leukemia cells, which has be-come an effective treatment for intermediate and high-risk hematologic diseases. The donor T lymphocytes of GVL undergo the process of activation, expansion and effector to remove leukemia cells, and become an effective treatment for medium and high-risk hematological diseases. T lym-phocytes are the main effector cells to exert the graft-versus-leukemia effect, and play an important role in post-transplantation infections, GVHD, and relapses. PD-1, TIM-3, LAG-3, and CD47 inhibit the T cells to exert the immune effect by different mechanisms, so the allogeneic hematopoietic stem cells can be used for the treatment of leukemia through different mechanisms. PD-1, TIM-3, LAG-3, and CD47 inhibit T cells from exerting immune effects through different mechanisms, so the study of the reconstruction pattern of T lymphocytes and the above mentioned immune checkpoints after allogeneic hematopoietic stem cell transplantation is of great significance for prognosis.
出处
《临床医学进展》
2023年第12期19206-19213,共8页
Advances in Clinical Medicine
